HIV/AIDS Clinical Trials

Find HIV/AIDS Clinical Trials Near You

HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department (PrEP-ED) Study

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Our primary objective is to increase HIV pre-exposure prophylaxis (PrEP) awareness and uptake among people who want, need, or would benefit from PrEP in Dallas, TX through a pilot program of immediate PrEP prescribing in the Parkland Memorial Hospital Emergency Department (ED) with linkage to PrEP clinic. Leveraging the previous work of the Parkland Center for Clinical Innovation (PCCI) which created an automated electronic health record (EHR) based HIV prediction tool and prior success with a robust ED HIV navigation program, a PrEP navigator would approach patients in the Parkland ED for PrEP initiation. Through standard care prescribing by their ED clinician, subjects would leave the ED with a prescription for rapid-start oral PrEP and a clinic appointment to persist on the PrEP modality of their choice which will include long-acting injectable options.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Able to comprehend and provide signed, written informed consent prior to initiation of study procedures.

• Negative HIV rapid test

• At least one of the following criteria:

‣ Requesting PrEP from their ED clinician

⁃ Score \>75% on the PCCI HIV Prediction Tool

⁃ Prior bacterial STI diagnosis

⁃ Seeking STI testing

⁃ Referred by their ED clinician as someone who otherwise meets a CDC PrEP indication

∙ • Clinician in the Parkland ED

Locations
United States
Texas
Parkland Health
RECRUITING
Dallas
Time Frame
Start Date: 2026-04-08
Estimated Completion Date: 2028-04-01
Participants
Target number of participants: 250
Treatments
Other: Participants who decide to receive PrEP (rapid start)
Rapid start of PrEP in the Emergency Department (ED)
Related Therapeutic Areas
Sponsors
Leads: University of Texas Southwestern Medical Center
Collaborators: Gilead Sciences

This content was sourced from clinicaltrials.gov